{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T20:36:49Z","timestamp":1782765409674,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["(No. 82274582"],"award-info":[{"award-number":["(No. 82274582"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"S&T Program of Hebei central guidance for local scientific and technological development funding projects","award":["No. 246Z7706G"],"award-info":[{"award-number":["No. 246Z7706G"]}]},{"name":"the Key Laboratory Construction Subsidy Fund Project","award":["No. 236790017H"],"award-info":[{"award-number":["No. 236790017H"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To identify the associations between thymic pathology and the prognosis of myasthenia gravis (MG) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this multicenter retrospective study, 1,254 myasthenia gravis (MG) patients who underwent thymectomy across four clinical centers were included. Participants were categorized by thymic pathology into thymomatous and non-thymomatous groups. Primary outcome was postoperative deterioration. Secondary outcomes comprised the proportion of patients achieving minimal manifestation status (MMS) within the first year after surgery and conversion from ocular MG (OMG) to generalized MG (GMG) within 2\u00a0years of symptom onset. Subgroup analyses assessed associations between world health organization (WHO) pathological type (both groups) or Masaoka stage (thymoma patients) and prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thymomas were associated with an increased risk of deterioration in both Cox regression (adjusted HR\u2009=\u20091.40 [1.18, 1.66],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and logistic regression analyses (1-year deterioration: adjusted OR\u2009=\u20091.59 [1.15, 2.20],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005; 3-year deterioration: adjusted OR\u2009=\u20091.40 [1.01, 1.94],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.047). Additionally, thymomas were linked to a higher conversion rate (adjusted OR\u2009=\u20092.37 [1.15, 4.86],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.019). However, thymoma showed no significant association with MMS (adjusted\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.682). In the thymoma subgroup, neither pathological type nor Masaoka stage was significantly associated with deterioration (pathological type: 1-year\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.069, 3-year\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.220; Masaoka stage: 1-year\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.944, 3-year\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.909), first-year MMS attainment (pathological type:\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.067; Masaoka stage:\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.579), or conversion rate (pathological type:\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.606; Masaoka stage:\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.163). Similarly, in the nonthymomatous group, WHO pathological type was not significantly correlated with deterioration (1-year\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.806, 3-year\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.654), MMS achieved (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.940), or conversion (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.755).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study demonstrated an association between thymoma and higher risks of clinical deterioration, which was independent of WHO pathological type or Masaoka stage.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-025-04509-w","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T15:21:14Z","timestamp":1765898474000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The prognosis of MG patients with different thymic pathology: a multicenter retrospective cohort study"],"prefix":"10.1186","volume":"23","author":[{"given":"Moli","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-He","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Ping","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Dong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Yan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"4509_CR1","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231213240","author":"H Wiendl","year":"2023","unstructured":"Wiendl H, Abicht A, Chan A, Della Marina A, Hagenacker T, Hekmat K, et al. Guideline for the management of myasthenic syndromes. Ther Adv Neurol Disord. 2023. https:\/\/doi.org\/10.1177\/17562864231213240.","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"4509_CR2","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1602489","volume":"375","author":"GI Wolfe","year":"2016","unstructured":"Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo H-C, Marx A, et al. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med. 2016;375(6):511\u201322.","journal-title":"N Engl J Med"},{"issue":"6","key":"4509_CR3","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/mus.26300","volume":"58","author":"H Kim","year":"2018","unstructured":"Kim H, Lim YM, Lee EJ, Oh YJ, Kim KK. Factors predicting remission in thymectomized patients with acetylcholine receptor antibody-positive myasthenia gravis. Muscle Nerve. 2018;58(6):796\u2013800.","journal-title":"Muscle Nerve"},{"issue":"2","key":"4509_CR4","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1053\/j.semtcvs.2016.04.002","volume":"28","author":"AJ Kaufman","year":"2016","unstructured":"Kaufman AJ, Palatt J, Sivak M, Raimondi P, Lee D-S, Wolf A, et al. Thymectomy for myasthenia gravis: complete stable remission and associated prognostic factors in over 1000 cases. Semin Thorac Cardiovasc Surg. 2016;28(2):561\u20138.","journal-title":"Semin Thorac Cardiovasc Surg"},{"issue":"1","key":"4509_CR5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.22599\/bioj.315","volume":"19","author":"L Wilson","year":"2023","unstructured":"Wilson L, Davis H. The role of thymoma and thymic hyperplasia as prognostic risk factors for secondary generalisation in adults with ocular myasthenia gravis: a systematic narrative review. Br Ir Orthopt J. 2023;19(1):108\u201319.","journal-title":"Br Ir Orthopt J"},{"issue":"5","key":"4509_CR6","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/mus.25983","volume":"57","author":"KY Teo","year":"2017","unstructured":"Teo KY, Tow SL, Haaland B, Gosavi TD, Jing-Liang LOO, Yew Long LO, et al. Low conversion rate of ocular to generalized myasthenia gravis in Singapore. Muscle Nerve. 2017;57(5):756\u201360.","journal-title":"Muscle Nerve"},{"issue":"7","key":"4509_CR7","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.ophtha.2015.03.010","volume":"122","author":"L Nagia","year":"2015","unstructured":"Nagia L, Lemos J, Abusamra K, Cornblath WT, Eggenberger ER. Prognosis of ocular myasthenia gravis. Ophthalmology. 2015;122(7):1517\u201321.","journal-title":"Ophthalmology"},{"issue":"1\u20132","key":"4509_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jns.2008.05.023","volume":"273","author":"Y-H Hong","year":"2008","unstructured":"Hong Y-H, Kwon S-B, Kim B-J, Kim BJ, Kim SH, Kim JK, et al. Prognosis of ocular myasthenia in Korea: a retrospective multicenter analysis of 202 patients. J Neurol Sci. 2008;273(1\u20132):10\u20134.","journal-title":"J Neurol Sci"},{"key":"4509_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ajo.2019.04.017","volume":"205","author":"TM Hendricks","year":"2019","unstructured":"Hendricks TM, Bhatti MT, Hodge DO, Chen JJ. Incidence, epidemiology, and transformation of ocular myasthenia gravis: a population-based study. Am J Ophthalmol. 2019;205:99\u2013105.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"4509_CR10","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.jtcvs.2007.05.015","volume":"134","author":"HK Kim","year":"2007","unstructured":"Kim HK, Park MS, Choi YS, Kim K, Shim YM, Han J, et al. Neurologic outcomes of thymectomy in myasthenia gravis: comparative analysis of the effect of thymoma. J Thorac Cardiovasc Surg. 2007;134(3):601\u20137.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"2","key":"4509_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/0022-510X(91)90260-E","volume":"106","author":"E Beghi","year":"1991","unstructured":"Beghi E, Antozzi C, Batocchi AP, Cornelio F, Cosi V, Evoli A, et al. Prognosis of myasthenia gravis: a multicenter follow-up study of 844 patients. J Neurol Sci. 1991;106(2):213\u201320.","journal-title":"J Neurol Sci"},{"issue":"5","key":"4509_CR12","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1016\/S0003-4975(02)04083-3","volume":"74","author":"M de Perrot","year":"2002","unstructured":"de Perrot M, Liu J, Bril V, McRae K, Bezjak A, Keshavjee SH. Prognostic significance of thymomas in patients with myasthenia gravis. Ann Thorac Surg. 2002;74(5):1658\u201362.","journal-title":"Ann Thorac Surg"},{"key":"4509_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-017-0857-7","author":"L Wang","year":"2017","unstructured":"Wang L, Zhang Y, He M. Clinical predictors for the prognosis of myasthenia gravis. BMC Neurol. 2017. https:\/\/doi.org\/10.1186\/s12883-017-0857-7.","journal-title":"BMC Neurol"},{"issue":"6","key":"4509_CR14","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1111\/ene.14820","volume":"28","author":"R \u00c1lvarez-Velasco","year":"2021","unstructured":"\u00c1lvarez-Velasco R, Guti\u00e9rrez-Guti\u00e9rrez G, Trujillo JC, Mart\u00ednez E, Segovia S, Arribas-Velasco M, et al. Clinical characteristics and outcomes of thymoma-associated myasthenia gravis. Eur J Neurol. 2021;28(6):2083\u201391.","journal-title":"Eur J Neurol"},{"key":"4509_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02454-y","author":"J Zhang","year":"2022","unstructured":"Zhang J, Zhang Z, Zhang H, Cui Y, Chen Y, Lv P, et al. Thymectomy in ocular myasthenia gravis\u2014prognosis and risk factors analysis. Orphanet J Rare Dis. 2022. https:\/\/doi.org\/10.1186\/s13023-022-02454-y.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"4509_CR16","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.21037\/jtd.2018.05.30","volume":"10","author":"J Shen","year":"2018","unstructured":"Shen J, Tie H, Xu A, Chen D, Ma D, Zhang B, et al. Inter-relationship among myasthenia gravis, WHO histology, and Masaoka clinical stage and effect on surgical methods in patients with thymoma: a retrospective cohort study. J Thorac Dis. 2018;10(5):2981\u201390.","journal-title":"J Thorac Dis"},{"key":"4509_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102337","author":"CMJ Lefeuvre","year":"2020","unstructured":"Lefeuvre CMJ, Payet CA, Fayet O-M, Maillard S, Truffault F, Bondet V, et al. Risk factors associated with myasthenia gravis in thymoma patients: the potential role of thymic germinal centers. J Autoimmun. 2020. https:\/\/doi.org\/10.1016\/j.jaut.2019.102337.","journal-title":"J Autoimmun"},{"issue":"4","key":"4509_CR18","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/mus.27169","volume":"63","author":"A Kim","year":"2021","unstructured":"Kim A, Choi SJ, Kang CH, Lee S, Son H, Kim JA, et al. Risk factors for developing post-thymectomy myasthenia gravis in patients with thymoma. Muscle Nerve. 2021;63(4):531\u20137.","journal-title":"Muscle Nerve"},{"key":"4509_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-03082-z","author":"Z Haoshuai","year":"2021","unstructured":"Haoshuai Z, Jianyong Z, Lei Y, Bo Z, Xiao J, Zhang X, et al. Factors affecting improvement of neurologic status evaluated by quantitative myasthenia gravis score for patients with thymomatous myasthenia gravis after extended thymectomy. J Transl Med. 2021. https:\/\/doi.org\/10.1186\/s12967-021-03082-z.","journal-title":"J Transl Med"},{"issue":"1","key":"4509_CR20","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/1759-7714.13724","volume":"12","author":"A De Rosa","year":"2020","unstructured":"De Rosa A, Fornili M, Maestri Tassoni M, Guida M, Baglietto L, Petrucci L, et al. Thymoma-associated myasthenia gravis: clinical features and predictive value of antiacetylcholine receptor antibodies in the risk of recurrence of thymoma. Thorac Cancer. 2020;12(1):106\u201313.","journal-title":"Thorac Cancer"},{"issue":"7 Suppl 3","key":"4509_CR21","doi-asserted-by":"publisher","first-page":"S1698","DOI":"10.1097\/JTO.0b013e31821e7b12","volume":"6","author":"F Detterbeck","year":"2011","unstructured":"Detterbeck F, Youssef S, Ruffini E, Okumura M. A review of prognostic factors in thymic malignancies. J Thorac Oncol. 2011;6(7 Suppl 3):S1698\u2013704.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"4509_CR22","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1093\/ejcts\/ezz334","volume":"57","author":"KY Chung","year":"2020","unstructured":"Chung KY, Paik HC, Kim DJ, Lee JG, Lee CY, Shim YM, et al. Predictors of post-thymectomy long-term neurological remission in thymomatous myasthenia gravis: an analysis from a multi-institutional database. Eur J Cardiothorac Surg. 2020;57(5):867\u201373.","journal-title":"Eur J Cardiothorac Surg"},{"issue":"6","key":"4509_CR23","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1002\/mus.27220","volume":"63","author":"D Menon","year":"2021","unstructured":"Menon D, Katzberg H, Barnett C, Pal P, Bezjak A, Keshavjee S, et al. Thymoma pathology and myasthenia gravis outcomes. Muscle Nerve. 2021;63(6):868\u201373.","journal-title":"Muscle Nerve"},{"issue":"7","key":"4509_CR24","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1007\/s00415-013-6880-8","volume":"260","author":"J Spillane","year":"2013","unstructured":"Spillane J, Hayward M, Hirsch NP, Taylor C, Kullmann DM, Howard RS. Thymectomy: role in the treatment of myasthenia gravis. J Neurol. 2013;260(7):1798\u2013801.","journal-title":"J Neurol"},{"issue":"1\u20132","key":"4509_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jns.2015.08.029","volume":"358","author":"M Jakub\u00edkov\u00e1","year":"2015","unstructured":"Jakub\u00edkov\u00e1 M, Pi\u0165ha J, Mare\u010dkov\u00e1 H, T\u00fdblov\u00e1 M, Nov\u00e1kov\u00e1 I, Schutzner J. Two-year outcome of thymectomy with or without immunosuppressive treatment in nonthymomatous myasthenia gravis and its effect on regulatory T cells. J Neurol Sci. 2015;358(1\u20132):101\u20136.","journal-title":"J Neurol Sci"},{"issue":"1","key":"4509_CR26","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/00000478-200101000-00012","volume":"25","author":"M Okumura","year":"2001","unstructured":"Okumura M, Miyoshi S, Fujii Y, Takeuchi Y, Shiono H, Inoue M, et al. Clinical and functional significance of WHO classification on human thymic epithelial neoplasms: a study of 146 consecutive tumors. Am J Surg Pathol. 2001;25(1):103\u201310.","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"4509_CR27","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1212\/01.WNL.0000032502.89361.0C","volume":"59","author":"A Evoli","year":"2002","unstructured":"Evoli A, Minisci C, Di Schino C, Marsili F, Punzi C, Batocchi AP, et al. Thymoma in patients with MG: characteristics and long-term outcome. Neurology. 2002;59(12):1844\u201350.","journal-title":"Neurology"},{"issue":"11","key":"4509_CR28","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/S0025-6196(12)60907-0","volume":"68","author":"TI Morgenthaler","year":"1993","unstructured":"Morgenthaler TI, Brown LR, Colby TV, Harper CM, Coles DT. Thymoma. Mayo Clin Proc. 1993;68(11):1110\u201323.","journal-title":"Mayo Clin Proc"},{"key":"4509_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109644","volume":"183","author":"L Chen","year":"2023","unstructured":"Chen L, Li Y, Dong X, Tanzhu G, Chu X, Deng F, et al. The value of postoperative radiotherapy in thymoma patients with myasthenia gravis. Radiother Oncol. 2023;183:109644.","journal-title":"Radiother Oncol"},{"key":"4509_CR30","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.critrevonc.2016.01.012","volume":"99","author":"M Scorsetti","year":"2016","unstructured":"Scorsetti M, Leo F, Trama A, D\u2019Angelillo R, Serpico D, Macerelli M, et al. Thymoma and thymic carcinomas. Crit Rev Oncol Hematol. 2016;99:332\u201350.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"4509_CR31","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jtho.2022.10.016","volume":"18","author":"CB Falkson","year":"2023","unstructured":"Falkson CB, Vella ET, Ellis PM, Maziak DE, Ung YC, Yu E. Surgical, radiation, and systemic treatments of patients with thymic epithelial tumors: a systematic review. J Thorac Oncol. 2023;18(3):299\u2013312.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"4509_CR32","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.athoracsur.2014.10.068","volume":"99","author":"Y Yamada","year":"2015","unstructured":"Yamada Y, Yoshida S, Iwata T, Suzuki H, Tagawa T, Mizobuchi T, et al. Risk factors for developing postthymectomy myasthenia gravis in thymoma patients. Ann Thorac Surg. 2015;99(3):1013\u20139.","journal-title":"Ann Thorac Surg"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04509-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-04509-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04509-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T03:03:05Z","timestamp":1765940585000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-025-04509-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4509"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-04509-w","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"assertion":[{"value":"12 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Tianjin Medical University General Hospital (No. IRB2025-YX-012-01) and formal waiver of informed consent was granted by the institutional review board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"FDS received honoraria (lectures, advisory boards, consultations) from Alexion\/AstraZeneca, Novartis, Hansoh Pharmaceutical, Sinomab and Lundbeck. He received research grants from Zai Lab, AstraZeneca, Novartis, Biogen. FDS was a co-founder of New Terrain from August, 2018 to December, 2019; Akriva from November, 2023 to September, 2025. He also serves as the current section chair of national network of Neuroimmunology, under Chinese neurological association from 2020 to present and as a board member of European Charcot Foundation from 2023 to present. All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"685"}}